CRESCENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CRESCENT BIOPHARMA, INC. (CBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 525.39 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 302.45K shares.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 222.94K shares.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 2.09M shares.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 345.44K shares.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.81M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 302.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 525.39K shares 10-Q · filed 2026-07-30 | 2.62M shares derived: sum of 3 quarters · filed 2026-07-30 | 2.96M shares derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | 222.94K shares 10-Q · filed 2026-04-29 | 2.32M shares derived: sum of 2 quarters · filed 2026-04-29 | 2.66M shares derived: sum of 3 quarters · filed 2026-04-29 | ||
| 2025-12-31 | 2.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 2.44M shares derived: sum of 2 quarters · filed 2026-02-26 | 5.81M shares 10-K · filed 2026-02-26 | ||
| 2025-09-30 | 345.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 3.72M shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 3.37M shares 10-Q · filed 2025-07-31 | ||||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-06 | ||||
| 2020-09-30 | 60.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | 100.60K shares 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | 40.60K shares 10-Q · filed 2020-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |